Compare GOOS & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GOOS | TYRA |
|---|---|---|
| Founded | 1957 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2017 | 2021 |
| Metric | GOOS | TYRA |
|---|---|---|
| Price | $13.12 | $25.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $12.40 | ★ $32.17 |
| AVG Volume (30 Days) | ★ 839.9K | 516.9K |
| Earning Date | 02-05-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $984,644,735.00 | N/A |
| Revenue This Year | $8.87 | N/A |
| Revenue Next Year | $5.93 | N/A |
| P/E Ratio | $68.59 | ★ N/A |
| Revenue Growth | ★ 3.71 | N/A |
| 52 Week Low | $6.73 | $6.42 |
| 52 Week High | $15.43 | $26.34 |
| Indicator | GOOS | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 50.62 | 71.18 |
| Support Level | $12.47 | $24.88 |
| Resistance Level | $13.25 | $26.34 |
| Average True Range (ATR) | 0.38 | 1.27 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 78.85 | 81.62 |
Canada Goose Holdings Inc is a Canada-based company that designs, manufactures, distributes, and retails premium outerwear for men, women, and children. It operates business through three segments namely, Wholesale and Direct to Consumer (DTC), Other. The DTC segment, which is the key revenue driver, comprises sales through country-specific e-commerce platforms and its company-owned retail stores located in luxury shopping locations. The Wholesale segment comprises sales made to a mix of retailers and international distributors, who are partners that have exclusive rights to an entire market, and travel retail locations. Geographically, it has a presence in Canada, the United States, North America, Greater China, Asia, and Europe, the Middle East, and Africa.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.